Item type | Home library | Collection | Class number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|
UNKNOWN | Ferriman Information and Library Service (North Middlesex) Online | Staff publications for NMDX | Available |
NMUH Staff Publications
Available in print at Ferriman Library
106
<p style="margin: 0px 0px 0.5em; line-height: 17.999801635742188px;"><span style="font-size: 8pt;"><strong>OBJECTIVE:</strong> To describe our initial outcome data&nbsp;<span class="highlight">following</span>&nbsp;a&nbsp;<span class="highlight">shortened</span>&nbsp;<span class="highlight">6-week</span>&nbsp;<span class="highlight">treatment</span>&nbsp;<span class="highlight">protocol</span>&nbsp;with&nbsp;<span class="highlight">percutaneous</span>&nbsp;<span class="highlight">tibial</span><span class="highlight">nerve</span>&nbsp;<span class="highlight">stimulation</span>&nbsp;(PTNS) in women with overactive bladder syndrome (OABS) unresponsive to bladder retraining and anticholinergic therapy.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; line-height: 17.999801635742188px;"><span style="font-size: 8pt;">PATIENTS AND METHODS:</span></h4><p style="margin: 0px 0px 0.5em; line-height: 17.999801635742188px;"><span style="font-size: 8pt;">This was a prospective observational study over a 6-month period. In all, 43 women with OABS refractory to medical therapy were treated with a&nbsp;<span class="highlight">shortened</span>&nbsp;PTNS&nbsp;<span class="highlight">protocol</span>&nbsp;that consisted of 6 weekly 30 min sessions. Bladder symptom diaries and health-related quality of life (HRQL) assessed using the short-form seven-item self-report. Incontinence Impact Questionnaire (IIQ-7) were completed before and after&nbsp;<span class="highlight">treatment</span>. A positive response was defined as: (i) OAB symptoms no longer being bothersome; (ii) reduction by half in frequency episodes and (iii) reduction by 25% in IIQ-7<span class="highlight">outcomes</span>.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; line-height: 17.999801635742188px;"><span style="font-size: 8pt;">RESULTS:</span></h4><p style="margin: 0px 0px 0.5em; line-height: 17.999801635742188px;"><span style="font-size: 8pt;">All 43 women (median age 55.3 years) completed six treatments with a positive response rate of 69.7%. In the positive responders, the median daytime and nocturnal frequency was reduced by half after 6 weeks of&nbsp;<span class="highlight">treatment</span>&nbsp;(11.8 vs 6.9 and 3.5 vs 1.8, respectively, P &lt; 0.05) and the patients reported fewer urge leak episodes per 24 h (median 3.5 vs 2.4, P &lt; 0.05). The median IIQ-7 scores improved by 25% (30.4 vs 24.3, P &lt; 0.05) in responders, while the median number of pads changed in 24 h also decreased by 34% (3.8 vs 2.5, P &lt; 0.05). The median acceptability of the technique when scored by Visual Analogue Score was 9.6/10 and no side-effects were reported.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; line-height: 17.999801635742188px;"><span style="font-size: 8pt;">CONCLUSION:</span></h4><p style="margin: 0px 0px 0.5em; line-height: 17.999801635742188px;"><span style="font-size: 8pt;">A&nbsp;<span class="highlight">shortened</span>&nbsp;<span class="highlight">6-week</span>&nbsp;<span class="highlight">treatment</span>&nbsp;with PTNS appears to be successful, with a significant reduction in symptoms and improvement in HRQL. This early data suggest that the duration of&nbsp;<span class="highlight">treatment</span>&nbsp;for peripheral neuromodulation can be halved compared with the conventional 12 weeks, which would make it more acceptable and cost effective for patients. A randomised controlled trial of 6 weeks vs 12 weeks of PTNS therapy would be useful in determining the optimal duration of&nbsp;<span class="highlight">treatment</span></span></p>
There are no comments on this title.